CL2012000715A1 - Compuesto agonista del receptor de peptido natriuretico b (npr-b), que comprende peptidos lineales que contienen 9 residuos aminoacidicos; y su uso para preparar un medicamento para disminuir la presion intraocular. - Google Patents
Compuesto agonista del receptor de peptido natriuretico b (npr-b), que comprende peptidos lineales que contienen 9 residuos aminoacidicos; y su uso para preparar un medicamento para disminuir la presion intraocular.Info
- Publication number
- CL2012000715A1 CL2012000715A1 CL2012000715A CL2012000715A CL2012000715A1 CL 2012000715 A1 CL2012000715 A1 CL 2012000715A1 CL 2012000715 A CL2012000715 A CL 2012000715A CL 2012000715 A CL2012000715 A CL 2012000715A CL 2012000715 A1 CL2012000715 A1 CL 2012000715A1
- Authority
- CL
- Chile
- Prior art keywords
- npr
- agonist compound
- intraocular pressure
- natriuretic peptide
- drug
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000004410 intraocular pressure Effects 0.000 title abstract 3
- 125000000539 amino acid group Chemical group 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 102000027424 natriuretic peptide receptors Human genes 0.000 title 1
- 108091008599 natriuretic peptide receptors Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 102100039341 Atrial natriuretic peptide receptor 2 Human genes 0.000 abstract 5
- 101710102159 Atrial natriuretic peptide receptor 2 Proteins 0.000 abstract 5
- 239000000556 agonist Substances 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 102100031478 C-type natriuretic peptide Human genes 0.000 abstract 2
- 101000796277 Homo sapiens C-type natriuretic peptide Proteins 0.000 abstract 2
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24596009P | 2009-09-25 | 2009-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012000715A1 true CL2012000715A1 (es) | 2012-11-30 |
Family
ID=43781057
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012000715A CL2012000715A1 (es) | 2009-09-25 | 2012-03-22 | Compuesto agonista del receptor de peptido natriuretico b (npr-b), que comprende peptidos lineales que contienen 9 residuos aminoacidicos; y su uso para preparar un medicamento para disminuir la presion intraocular. |
| CL2017001190A CL2017001190A1 (es) | 2009-09-25 | 2017-05-11 | Nuevos agonistas de npr-b. (divisional de solicitud 715-2012) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001190A CL2017001190A1 (es) | 2009-09-25 | 2017-05-11 | Nuevos agonistas de npr-b. (divisional de solicitud 715-2012) |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US8546523B2 (enExample) |
| EP (1) | EP2480247B1 (enExample) |
| JP (3) | JP5893561B2 (enExample) |
| KR (3) | KR20180049198A (enExample) |
| CN (2) | CN102548574B (enExample) |
| AR (1) | AR078445A1 (enExample) |
| AU (1) | AU2010298256B2 (enExample) |
| BR (1) | BR112012006579A2 (enExample) |
| CA (1) | CA2773949C (enExample) |
| CL (2) | CL2012000715A1 (enExample) |
| MX (3) | MX2012003398A (enExample) |
| PH (1) | PH12012500562A1 (enExample) |
| RU (3) | RU2636738C2 (enExample) |
| TW (2) | TWI577384B (enExample) |
| UY (1) | UY32902A (enExample) |
| WO (1) | WO2011038061A2 (enExample) |
| ZA (3) | ZA201201630B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732406B2 (en) | 2005-04-07 | 2010-06-08 | Cardiopep Pharma Gmbh | Use of natriuretic peptide for treating heart failure |
| JP5345532B2 (ja) * | 2006-08-02 | 2013-11-20 | ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ | Ｌｃｔ中毒に対する医薬品 |
| PH12012500562A1 (en) | 2009-09-25 | 2012-10-22 | Takeda Pharmaceuticals Co | Novel npr-b antagonists |
| TW201121995A (en) | 2009-12-18 | 2011-07-01 | Alcon Res Ltd | Novel NPR-B agonists |
| CA2853204A1 (en) * | 2011-12-16 | 2013-06-20 | Kalos Therapeutics, Inc. | Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases |
| NZ710246A (en) * | 2013-01-25 | 2016-11-25 | Cardiorentis Ltd | Methods of treating cardiovasular indications |
| SI3464336T1 (sl) | 2016-06-01 | 2022-06-30 | Athira Pharma, Inc. | Spojine |
| EP3576770A1 (en) * | 2017-02-01 | 2019-12-11 | Shire Human Genetic Therapies, Inc. | Compounds and compositions for the treatment of ophthalmic disorders |
| CA3056433A1 (en) | 2017-03-22 | 2018-09-27 | Pharmain Corporation | Npra agonists, compositions, and uses thereof |
| US20210121534A1 (en) * | 2018-06-19 | 2021-04-29 | Cella Therapeutics, Llc | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension |
| EP3880685B1 (en) * | 2018-11-16 | 2025-06-18 | Arcus Biosciences, Inc. | Inhibitors of arg1 and/or arg2 |
| US20230416328A1 (en) * | 2020-06-12 | 2023-12-28 | Hirofumi Tachibana | C-Type Natriuretic Peptides and Methods Thereof in Treating Acute Lung Injury |
| KR102677730B1 (ko) * | 2023-03-27 | 2024-06-27 | 나인바이오팜 주식회사 | 지방 분해 효능을 갖는 펩타이드 및 이의 용도 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757048A (en) | 1985-11-05 | 1988-07-12 | Biotechnology Research Associates J.V. | Synthetic analogs of atrial natriuretic peptides |
| EP0323740A3 (en) * | 1987-12-24 | 1990-12-12 | California Biotechnology, Inc. | Linear analogs of atrial natriuretic peptides |
| JP2848411B2 (ja) * | 1988-08-18 | 1999-01-20 | サイオス インコーポレイテッド | 心房性ナトリウム利尿ペプチドクリアランス阻害剤 |
| EP1118329A4 (en) | 1998-09-28 | 2004-12-15 | Santen Pharmaceutical Co Ltd | LACRYMAL SECRETION PROMOTERS OR OPHTHALMOLOGICAL DROPS CONTAINING NATRIURETIC PEPTIDES AS ACTIVE INGREDIENTS FOR TREATING KERATOCONJUNCTIVITY |
| US20040266673A1 (en) * | 2002-07-31 | 2004-12-30 | Peter Bakis | Long lasting natriuretic peptide derivatives |
| US6025198A (en) | 1999-06-25 | 2000-02-15 | Isis Pharmaceuticals Inc. | Antisense modulation of Ship-2 expression |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| IL142118A0 (en) * | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| TWI231759B (en) * | 2001-06-27 | 2005-05-01 | Alcon Inc | Olopatadine formulations for topical administration |
| US7648962B2 (en) * | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
| US7297709B2 (en) * | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| WO2006005140A2 (en) * | 2004-07-15 | 2006-01-19 | The University Of Queensland | Proteinaceous compounds and uses therefor |
| TW200640443A (en) * | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| WO2007034498A1 (en) * | 2005-09-26 | 2007-03-29 | Compugen Ltd. | Atrial natriuretic peptide (anp) splice variants and methods of using same |
| CA2625600A1 (en) * | 2005-10-14 | 2007-04-26 | Biorexis Pharmaceutical Corporation | Natriuretic peptide modified transferrin fusion proteins |
| AU2007233116B2 (en) * | 2006-03-30 | 2013-05-09 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
| AU2007233123A1 (en) * | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Linear natriuretic peptide constructs |
| AR069409A1 (es) * | 2007-11-21 | 2010-01-20 | Biomarin Pharm Inc | Variantes de peptidos natriureticos de tipo c |
| PH12012500562A1 (en) | 2009-09-25 | 2012-10-22 | Takeda Pharmaceuticals Co | Novel npr-b antagonists |
| US8551938B2 (en) | 2009-09-25 | 2013-10-08 | Alcon Research, Ltd. | NPR-B agonists |
| TW201121995A (en) | 2009-12-18 | 2011-07-01 | Alcon Res Ltd | Novel NPR-B agonists |
-
2010
- 2010-09-23 PH PH1/2012/500562A patent/PH12012500562A1/en unknown
- 2010-09-23 MX MX2012003398A patent/MX2012003398A/es active IP Right Grant
- 2010-09-23 CN CN201080042799.0A patent/CN102548574B/zh not_active Expired - Fee Related
- 2010-09-23 KR KR1020187012130A patent/KR20180049198A/ko not_active Ceased
- 2010-09-23 WO PCT/US2010/049912 patent/WO2011038061A2/en not_active Ceased
- 2010-09-23 US US12/888,556 patent/US8546523B2/en not_active Expired - Fee Related
- 2010-09-23 KR KR1020127010423A patent/KR101768661B1/ko not_active Expired - Fee Related
- 2010-09-23 RU RU2015124607A patent/RU2636738C2/ru active
- 2010-09-23 AU AU2010298256A patent/AU2010298256B2/en not_active Ceased
- 2010-09-23 JP JP2012531012A patent/JP5893561B2/ja not_active Expired - Fee Related
- 2010-09-23 RU RU2012116531/04A patent/RU2557290C2/ru active
- 2010-09-23 MX MX2014001528A patent/MX354005B/es unknown
- 2010-09-23 MX MX2017012681A patent/MX370645B/es unknown
- 2010-09-23 KR KR1020177022310A patent/KR101854820B1/ko not_active Expired - Fee Related
- 2010-09-23 EP EP10819424.2A patent/EP2480247B1/en active Active
- 2010-09-23 BR BR112012006579A patent/BR112012006579A2/pt not_active Application Discontinuation
- 2010-09-23 CA CA2773949A patent/CA2773949C/en not_active Expired - Fee Related
- 2010-09-23 CN CN201610116122.6A patent/CN105732767A/zh active Pending
- 2010-09-23 UY UY0001032902A patent/UY32902A/es not_active Application Discontinuation
- 2010-09-24 TW TW099132370A patent/TWI577384B/zh not_active IP Right Cessation
- 2010-09-24 TW TW104137551A patent/TWI625126B/zh not_active IP Right Cessation
- 2010-09-24 AR ARP100103479A patent/AR078445A1/es active IP Right Grant
-
2012
- 2012-03-05 ZA ZA2012/01630A patent/ZA201201630B/en unknown
- 2012-03-22 CL CL2012000715A patent/CL2012000715A1/es unknown
-
2013
- 2013-08-28 US US14/011,855 patent/US9169293B2/en not_active Expired - Fee Related
-
2014
- 2014-03-04 ZA ZA2014/01625A patent/ZA201401625B/en unknown
-
2015
- 2015-04-21 JP JP2015086575A patent/JP6211032B2/ja not_active Expired - Fee Related
- 2015-08-12 US US14/824,353 patent/US9745344B2/en not_active Expired - Fee Related
-
2017
- 2017-04-26 ZA ZA2017/02958A patent/ZA201702958B/en unknown
- 2017-05-11 CL CL2017001190A patent/CL2017001190A1/es unknown
- 2017-05-22 JP JP2017101128A patent/JP2017137362A/ja not_active Withdrawn
- 2017-07-10 US US15/645,680 patent/US9982016B2/en not_active Expired - Fee Related
- 2017-11-16 RU RU2017139870A patent/RU2017139870A/ru unknown
-
2018
- 2018-05-09 US US15/975,172 patent/US10196423B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065349A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| PE20100255A1 (es) | Co-agonistas del receptor de glucagon/glp-1 | |
| CL2020002796A1 (es) | Derivados de gip y usos de estos | |
| PE20211992A1 (es) | Proceso para preparar un agonista dual de gip/glp1 | |
| AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
| PE20170087A1 (es) | Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon | |
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| PE20241305A1 (es) | Analogos de amilina | |
| PE20240015A1 (es) | Proteinas de fusion gdf15 y usos de estas | |
| AR087973A1 (es) | Variantes del factor 21 del crecimiento de fibroblastos | |
| PE20090932A1 (es) | Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 | |
| AR093903A1 (es) | Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad | |
| CL2020002574A1 (es) | Análogos novedosos de glp-1 | |
| PE20221518A1 (es) | Analogos de incretina y sus usos | |
| PE20231639A1 (es) | Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1) | |
| PE20190470A1 (es) | Nuevos analogos de urocortina-2 modificados con acido graso para el tratamiento de diabetes y enfermedad renal cronica | |
| AR070276A1 (es) | Composicion que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas. formulacion farmaceutica. usos. metodo de preparacion. | |
| AR074397A1 (es) | Polipéptidos receptores de activina iib estabilizados y usos de los mismos | |
| PE20090682A1 (es) | Secuencias peptidicas y composiciones | |
| PE20200678A1 (es) | Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2) | |
| JP2013532176A5 (enExample) | ||
| CL2019003410A1 (es) | Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407). | |
| MX2015002994A (es) | Peptidos de inhibidores obtenidos del receptor desencadenante expresado en celulas mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos. | |
| PE20181176A1 (es) | Composiciones biofarmaceuticas | |
| AR091866A1 (es) | Analogos del glucagon |